SciSparc Ltd.
SPRC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SPRC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SPRC
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company developing cannabinoid-based therapies, currently generating no pharmaceutical revenue and facing significant financial uncertainty.
Key risk: Going concern uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$151.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2025.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company developing cannabinoid-based therapies, currently generating no pharmaceutical revenue and facing significant financial uncertainty.
- SciSparc is a clinical-stage pharmaceutical company with no revenue from pharmaceutical product sales [sec · filed 2026-04-29].
- As of December 31, 2025, cash was approximately $4.6 million, with an accumulated deficit of approximately $87 million [sec · filed 2026-04-29].
- The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern [sec · filed 2026-04-29].
- SciSparc received FDA clearance to proceed under an IND in October 2024, enabling a U.S. clinical trial [sec · filed 2026-04-29].
- The company has begun early commercialization efforts for its PEA oral tablet formulation, CannAmide™, in Canada [sec · filed 2026-04-29].
What works
- SciSparc received FDA clearance to proceed under an IND in October 2024, allowing a U.S. clinical trial [sec · filed 2026-04-29].
- The company has initiated early commercialization efforts for CannAmide™ in Canada, which may generate initial revenue [sec · filed 2026-04-29].
- The FDA did not oppose a 505(b)(2) NDA pathway for dronabinol-based products, potentially reducing development time and cost [sec · filed 2026-04-29].
What to weigh
- SciSparc has incurred significant losses since inception and expects to continue doing so until it can generate revenue [sec · filed 2026-04-29].
- The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern [sec · filed 2026-04-29].
- As of December 31, 2025, cash was only $4.6 million with an accumulated deficit of $87 million, indicating a need for substantial additional funding [sec · filed 2026-04-29].
- All pharmaceutical product candidates are in late preclinical or early clinical stages, with no pivotal studies yet initiated [sec · filed 2026-04-29].
From the filings
Quoted directly from source documents.
The company has no pharmaceutical revenue and is in early development stages.
“We currently generate no revenue from sales of any pharmaceutical product candidate, and we may never be able to develop or commercialize a marketable pharmaceutical product candidate.”
SEC filings · April 29, 2026
The auditor has raised going concern doubts.
“The report of our independent registered public accounting firm on our audited consolidated financial statements for the period ended December 31, 2025, contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern.”
SEC filings · April 29, 2026
FDA clearance was obtained in October 2024 for a U.S. clinical trial.
“In October 2024, we received FDA clearance to proceed under our IND, enabling us to conduct the clinical trial in the United States.”
SEC filings · April 29, 2026
Cash and accumulated deficit as of December 31, 2025.
“As of December 31, 2025, our cash was approximately $4.6 million, other accounts receivable was approximately $0.3 million, we had working capital of approximately $3.2 million and we also had an accumulated deficit of approximately $87 million.”
SEC filings · April 29, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Auditor has expressed substantial doubt about ability to continue as a going concern [sec · filed 2026-04-29].
- Cash runway limited — Cash of $4.6M as of Dec 31, 2025 may not be sufficient to fund operations [sec · filed 2026-04-29].
- No approved products — All candidates are in late preclinical or early clinical stages; no revenue from pharmaceutical sales [sec · filed 2026-04-29].
- Need for additional funding — Substantial additional capital required; may not be available on acceptable terms [sec · filed 2026-04-29].
What to watch
- Initiation of the U.S. clinical trial following FDA IND clearance in October 2024 [sec · filed 2026-04-29].
- Progress of early commercialization of CannAmide™ in Canada and any distribution agreements [sec · filed 2026-04-29].
- Ability to raise additional capital to fund operations and development [sec · filed 2026-04-29].
- Any updates on the terminated AutoMax merger and potential strategic alternatives [sec · filed 2026-04-29].
Sources: SEC filings · Generated August 27, 2026 · How we verify sources →
Run SciSparc Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SciSparc Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Cash runway data unavailable
OCF -$5M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2
Total value held
$487
| Holder | Shares | Value |
|---|---|---|
| strategic investment solutions, inc. /il | 133 | $487 |
| rhumbline advisers | 0 | $0 |
Short Interest
as of Apr 30, 2026- % of float
- 5.5%
- Days to cover
- 2.5
- Shares short
- 30,800
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SPRC short interestFrequently asked questions
What is the AI investment thesis for SciSparc Ltd.?
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company developing cannabinoid-based therapies, currently generating no pharmaceutical revenue and facing significant financial uncertainty.
Who is the CEO of SciSparc Ltd.?
Mr. Oz Adler CPA is the chief executive officer of SciSparc Ltd. (SPRC).
Where is SciSparc Ltd. headquartered?
SciSparc Ltd. (SPRC) is headquartered in Tel Aviv-Yafo, Israel.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.